Clinical protocols for the treatment of gastrointestinal cancer

在美国，胃肠癌是肿瘤相关死亡的主要原因之一。目前的治疗选择仅限于手术、化疗、放射治疗和分子靶向治疗，迫切需要新的治疗选择。我们一直在按以下方案招募患者：NCI-20-C-0022：转移性结直肠癌(MCRC)患者VB-111联合Nivolumab的II期试验。NCI-19-C-0033：Nivolumab(抗PD1)、他达拉非和口服万古霉素在难治性原发性肝细胞癌或结直肠癌或胰腺癌肝优势转移癌患者中的第二阶段研究；NCI-17-C-0092：Pexa-Vec溶瘤病毒结合免疫检查点抑制治疗难治性结直肠癌的I/II期研究；NCI-16-C-0135：联合免疫检查点抑制结合消融治疗在肝细胞癌(HCC)或胆道癌(BTC)患者中的试点研究；.19C0094 A：Durvalumab、Bevacizumab、Tremlimumab和肝细胞癌(BTC)患者经动脉化疗栓塞术(TACE)联合治疗的第二阶段研究。NCI-21-C-0030：针对表达GPC3的晚期GPC3的CAR-T细胞治疗的第一阶段研究；NCI-20-C-0152：曲美替尼(MEK抑制剂)和羟基氯喹(自噬抑制物)联合治疗KRAS突变难治性胆道癌(BTC)的第二阶段研究。

Gastrointestinal cancer represents one of the major reasons for tumor related death in the United States. Current treatment options are limited to surgery, chemotherapy, radiation therapy and molecular targeted therapy and new treatment options are urgently needed. We have been enrolling patients on the following protocols:NCI-20-C-0022: Phase II trial of VB-111 in Combination with Nivolumab in Patients with Metastatic Colorectal Cancer (mCRC). NCI-19-C-0033:Phase II Study of Nivolumab (anti-PD1), Tadalafil and Oral Vancomycin in Patients with Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer from Colorectal or Pancreatic Cancers; NCI-17-C-0092: A Phase I/II Study of Pexa-Vec Oncolytic Virus in Combination with Immune Checkpoint Inhibition in Refractory Colorectal Cancer; NCI-16-C-0135: A Pilot Study of Combined Immune Checkpoint Inhibition in combination with ablative therapies in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC) ;.19C0094 A: A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC).NCI-21-C-0030: Phase I Study of GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Hepatocellular Carcinoma (HCC); NCI-20-C-0152: Phase II Study of combination of Trametinib (MEK inhibitor) and Hydroxychloroquine (HCQ) (autophagy inhibitor) in Patients with KRAS Mutation Refractory Bile Tract Carcinoma (BTC).